Biomea Fusion, Inc.
BMEADrugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Aug 4, 2026
26dMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
How BMEA's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
BMF-219 | Phase 2 | Type 2 Diabetes Mellitus | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Biomea Fusion, Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Biomea Fusion, Inc.'s (BMEA) pipeline across Phase 2. Its lead program is BMF-219 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Biomea Fusion, Inc.'s next FDA catalyst?→
Biomea Fusion, Inc.'s (BMEA) next tracked catalyst is a Earnings expected August 4, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track BMEA biotech catalysts?→
Add BMEA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Biomea Fusion, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.